Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Nivolumab and ipilimumab for metastatic kidney cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.09.17
Views: 1823

Dr Bernard Escudier - Institut Gustave Roussy, Villejuif, France

Dr Escudier speaks with ecancer at ESMO 2017 about the results of Checkmate 214, a trial combining PD-1 and CTLA-4 targeted therapies to treat metastatic renal cell carcinoma, compared to current therapy sunitinib.

While most patients responded better to the combination of nivolumab and ipilimumab, Dr Escudier notes that a small subset of patients who had good prospects at diagnosis and a low presence of PDL-1 on tumour cells may yet benefit from sunitinib or cabozantinib, which has also proven effective in treating mRCC.

For more on these findings, watch Dr Escudier present the results at a press session here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

CML Life Banner

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation